Four Yale Researchers Honored at the 2022 Association for Clinical and Translational Science Awards
The collaboration that advanced the discovery of ketamine as a treatment for depression was among four Yale award winners at the Association for Clinical and Translational Science (ACTS) annual meeting held in Chicago from April 20 through 22.
Linda Coleman accepts appointment to the Board of Directors, Association for the Accreditation of Human Research Protection Programs
Linda Coleman, JD, the Director of the Yale Human Research Protection Program (HRPP), which assists Yale University in meeting its ethical and regulatory obligations for the protection of human research participants, has accepted an appointment to the Board of Directors of the Association for the Accreditation of Human Research Protection Programs (AAHRPP).
YCCI’s Tesheia Johnson Appointed to CTSA Steering Committee
The National Center for Advancing Translational Sciences (NCATS) has announced the new members of its Clinical and Translational Science Awards (CTSA) Program steering committee, including Yale School of Medicine Director of Clinical Research and Yale Center for Clinical Investigation (YCCI) Chief Operating Officer Tesheia Johnson, MBA, MHS. The steering committee provides direction to NCATS and the more than 60 CTSA-funded institutions around the country, including Yale.
Yale doctor on CT’s positivity rate nearing 5%, latest research on Moderna’s vaccine, unvaccinated discouraged from Labor Day travel
Yale Infectious Disease expert, Dr. Onyema Ogbuagu discusses CT’s positivity rate nearing 5%, latest research on Moderna’s vaccine, unvaccinated discouraged from Labor Day travelSource: WTNH
New Clinical Trial Evaluates Cardiovascular Outcomes in Tricuspid Valve Repair Without Open Heart Surgery
Investigators at the Yale School of Medicine are participating in an international study to evaluate the clinical outcomes of TriClip, the first non-surgical minimally invasive tricuspid valve repair device developed by Abbott.
Herold is New Chair of International Diabetes Consortium
Kevan C. Herold, MD, C.N.H. Long Professor of Immunobiology and professor of medicine (endocrinology) at Yale School of Medicine, has been named chair of Type 1 Diabetes (T1D) TrialNet, an international consortium dedicated to finding ways to prevent, delay, and slow progression of the disease.
Waterbury Black church leaders, Yale team up to dispel myths about COVID vaccine for communities of color, seniors
In Waterbury, an aggressive effort to take the COVID-19 vaccine to hard-to-reach communities embarked on another chapter Friday. This time, one of the city’s most popular Black churches engaged in something unique to shatter some vaccine myths.Source: WTNH
COVID-19: Being a part of research to make a change
Much like the rest of the world, I have been very aware of just how serious the COVID-19 pandemic is--a health crisis in need of immediate action with African Americans dying at twice the rate and hospitalized at almost three times that of our white counterparts. So, when I was given the opportunity to participate in the vaccine trial to fight the SARS-CoV-2 virus, I knew right away that it was my inherent duty as a community leader to sign up. As a Yale Cultural Ambassador and pastor for Walter’s Memorial AME Zion Church, it felt like such a significant way to further encourage members of my community to participate right alongside me, to drive health equity in our own community and advance science at the same time.
Bishop Kenneth Monroe: Prostate Cancer Survivor "Facing Uncertainty through Faith"
It was in the year 2000 when the Rev. Dr. Kenneth Monroe, then-pastor of the Metropolitan AME Zion Church, Hartford, CT noticed the need for more frequent bathroom breaks. Moreover, he realized that it was important to tell his doctor as soon as possible. He went for a physical and a prostate cancer screening which showed that his PSA count was 12.8. His doctor referred him to an urologist who ordered a prostate biopsy. The tissue was positive for cancer.
COVID-19: Making a Difference, Together
Vanessa Clayton’s story about clinical trials participation differs from most, as she was first approached to participate by her husband, Reverend Elvin Clayton, the pastor of the Walters Memorial AME Zion Church in Bridgeport, Connecticut and Cultural Ambassador to clinical research at Yale. Like many people of color, Mrs. Clayton was worried about the disproportionate impact of the COVID-19 virus on black and brown individuals. When her husband told her about the Phase 3 randomized and placebo-controlled trial looking to test the safety, tolerability, and immunogenicity of the SARS CoV 2 RNA vaccine against COVID-19, she did not immediately say yes. She decided to do her own homework to understand the research and also wanted to discuss it with family members in the health profession. Ultimately, after speaking to the study PI, Dr. Onyema Ogbuagu, and reviewing the informed consent, she decided to join her husband and hundreds of other Connecticut residents enrolling in the trial.